- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.05. | Immunovia AB: Bulletin From The Annual General Meeting On 13 May 2026 In Immunovia AB (publ) | 222 | GlobeNewswire (Europe) | Today, on 13 May 2026, the annual general meeting of Immunovia AB (publ) was held. A summary of the adopted resolutions follows below.
Resolution on the adoption of the accounts and allocation of resultThe... ► Artikel lesen | |
| 07.05. | Immunovia AB: Immunovia Publishes Interim Report for January-March 2026 | 336 | GlobeNewswire (Europe) | Highlights January-March 2026Net sales and operating results for Q1 2026 in line with expectations: Net sales of 374 KSEK (139) for the period included royalties and revenues from PancreaSure tests.... ► Artikel lesen | |
| 24.02. | Immunovia AB: Immunovia Publishes Full Year Report for 2025 | 615 | GlobeNewswire (Europe) | Highlights October-December 2025Net sales and operating results for Q4 2025 in line with expectations: Net sales of 354 KSEK for the period (455) largely reflected royalty revenue. Operating loss was... ► Artikel lesen | |
| 20.01. | Immunovia AB: The Board of Directors of Immunovia withdraws proposal for reverse share split and cancels Extraordinary General Meeting | 197 | GlobeNewswire (Europe) | Following discussions with major shareholders, the Board of Directors of Immunovia AB (publ) ("Immunovia" or the "Company") has decided to withdraw the proposal for a reverse share split and the Extraordinary... ► Artikel lesen | |
| 19.01. | Immunovia AB: Immunovia receives state regulatory approval for PancreaSure in California and initiates commercial rollout | 298 | GlobeNewswire (Europe) | Immunovia AB (IMMNOV: Nasdaq Stockholm), a pancreatic cancer diagnostics company, today announced that it has received regulatory approval for its PancreaSure test in California, US, enabling commercial... ► Artikel lesen | |
| 17.12.25 | Immunovia AB: The Board of Directors of Immunovia proposes a reverse share split | 762 | GlobeNewswire (Europe) | The Board of Directors of Immunovia AB (publ) ("Immunovia" or the "Company") proposes that an Extraordinary General Meeting on 22 January 2026 resolves to carry out a reverse share split, in the ratio... ► Artikel lesen | |
| 26.11.25 | Immunovia AB: Immunovia receives final Medicare payment rate for PancreaSure test | 336 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced that the Centers for Medicare & Medicaid Services (CMS) has finalized a national payment... ► Artikel lesen | |
| 26.11.25 | Immunovia AB: Immunovia Publishes Interim Report for July-September 2025 | 419 | GlobeNewswire (Europe) | Highlights July-September 2025Net sales and operating loss for Q3 2025 in line with expectations: Net sales of 101 KSEK for the period (235) largely reflected royalty revenue. Operating loss was 25.5... ► Artikel lesen | |
| IMMUNOVIA Aktie jetzt für 0€ handeln | |||||
| 03.10.25 | Immunovia AB: Immunovia publishes information document regarding rights issue | 577 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 01.10.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 01.10.2025 | 847 | Xetra Newsboard | Das Instrument RIHN CH0003671440 RIETER HLDG NA SF 5 EQUITY wird cum Kapitalmassnahme gehandelt am 01.10.2025 und ex Kapitalmassnahme am 02.10.2025 The instrument RIHN CH0003671440 RIETER HLDG NA SF... ► Artikel lesen | |
| 29.09.25 | Immunovia AB: Bulletin from the extraordinary general meeting in Immunovia AB (publ) | 770 | GlobeNewswire (Europe) | Today, on 29 September 2025, an extraordinary general meeting was held in Immunovia AB (publ). A summary of the adopted resolutions follows below.
Resolution on amendment of the Articles of AssociationThe... ► Artikel lesen | |
| 22.09.25 | Onconetix, Inc.: Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM | 667 | GlobeNewswire (Europe) | CINCINNATI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) ("Onconetix" or the "Company") a commercial stage biotechnology company focused on the research, development and commercialization... ► Artikel lesen | |
| 22.09.25 | Immunovia AB: Immunovia Secures Control of PancreaSure Supply Chain and Achieves Cost Reduction through Licensing Agreement | 489 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia AB (publ.), the pancreatic cancer diagnostics company, has announced the successful conclusion of an agreement to acquire assets and license intellectual property that will... ► Artikel lesen | |
| 15.09.25 | Immunovia AB: Inova Schar Cancer Adopts Immunovia's PancreaSure Test for its High-Risk Surveillance Program | 360 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia (publ.), the pancreatic cancer diagnostics company, today announced that its PancreaSure test will be offered to patients in Inova Schar Cancer's high-risk surveillance program... ► Artikel lesen | |
| 08.09.25 | Immunovia AB: Immunovia enters into top guarantee commitments for the upcoming rights issue | 358 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 28.08.25 | Immunovia AB: Immunovia Publishes Interim Report for January-June 2024 | 296 | GlobeNewswire (Europe) | April-June 2025Net sales, which for the quarter only included royalties, amounted to 90 KSEK (85).Operating loss was -20.1 MSEK, down from -23.9 MSEK in the second quarter of 2024. Net earnings were... ► Artikel lesen | |
| 27.08.25 | Immunovia AB: Immunovia carries out a rights issue of approximately SEK 100 million and secures bridge loans | 595 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 19.08.25 | Immunovia AB: Immunovia set to launch PancreaSure in the US on September 2nd, shares commercial strategy | 304 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia (publ.) the pancreatic cancer diagnostics company, today announced that the PancreaSure test is set to launch in the US on September 2nd. The company's initial focus will be... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HIMS & HERS HEALTH | 27,040 | -3,01 % | Hims & Hers-Aktie: Folgt der nächste Wachstumsturbo? | Die Aktie von Hims & Hers Health hat sich in den vergangenen Jahren zu einem der spektakulärsten Wachstumswerte im Gesundheitssektor entwickelt. Die operativen Kennzahlen sprechen weiterhin für erhebliches... ► Artikel lesen | |
| BECTON DICKINSON | 146,15 | -0,95 % | Becton, Dickinson Q4 2026 Earnings Preview | ||
| RYMAN HEALTHCARE | 1,020 | 0,00 % | XFRA RH7: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| WELLBEING DIGITAL SCIENCES | 0,007 | -100,00 % | KGK Science Receives Growth Investment Led By Maxim Partners | ||
| NIAGEN BIOSCIENCE | 2,540 | -15,89 % | Niagen Bioscience, Inc: Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168 | Collaboration will support pharmacokinetic, pharmacodynamic, and bioanalytical studies for Niagen Bioscience's lead investigational candidate for rare pediatric diseasesEvotec brings deep drug development... ► Artikel lesen | |
| SIENNA SENIOR LIVING | 14,000 | 0,00 % | Sienna Senior Living: Sienna Reports Second Quarter 2026 Financial Results and Forms Redevelopment Joint Venture with Fiera Infrastructure | MARKHAM, Ontario, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. ("Sienna" or the "Company") (TSX: SIA) today announced its financial results for the three and six months ended June 30... ► Artikel lesen | |
| MICROPORT SCIENTIFIC | 0,735 | -1,34 % | MICROPORT Subsidiary to Sell Over 44% Stake in Shanghai MicroPort Orthopedics, Receiving New Shares from TINAVI | ||
| EXTENDICARE | 21,400 | +0,94 % | Extendicare Inc.: Extendicare Announces July 2026 Dividend of C$0.0441 per Share | Markham, Ontario--(Newsfile Corp. - July 15, 2026) - Extendicare Inc. (TSX: EXE) ("Extendicare" or the "Company") announced that it has declared a cash dividend of C$0.0441 per common share of the... ► Artikel lesen | |
| VERADIGM | 7,350 | -100,00 % | Veradigm Inc. - 8-K, Current Report | ||
| NATIONAL HEALTHCARE CORPORATION | 178,00 | -5,32 % | Dividendenbekanntmachungen (30.06.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABACUS GROUP UTS AU0000291882 0,0212 AUD 0,0128 EUR ACADIA REALTY TRUST US0042391096 0,2 USD 0,175 EUR ACADIAN TIMBER CORP CA0042721005 0... ► Artikel lesen | |
| HANGZHOU TIGERMED CONSULTING | 4,080 | -2,86 % | Dividendenbekanntmachungen (18.06.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 3I GROUP PLC GB00B1YW4409 0,48 GBP 0,5547 EUR ACADEMY SPORTS AND OUTDOORS INC US00402L1070 0,15 USD 0,1303 EUR AEP PLANTATIONS... ► Artikel lesen | |
| UNIPHAR | 4,205 | +0,48 % | Uniphar PLC - Holding(s) in Company | ||
| AESTHETIC MEDICAL INTERNATIONAL | 0,009 | 0,00 % | XFRA 3FMA,833: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILAEST.MED.INT.HLD.SP.ADR/3... ► Artikel lesen | |
| FRESENIUS | 46,650 | +5,16 % | Fresenius hebt nach dem zweiten Quartal den Ergebnisausblick an | ||
| FRESENIUS MEDICAL CARE | 41,310 | -0,36 % | Rallye bei Palantir: Rekordjagd geht weiter: DAX startet mit Gewinnen nach Zahlenreigen | © Foto: Arne Dedert/dpaEuropas Börsen haben am Dienstag weiter zugelegt. Starke Vorgaben und die Berichtssaison stützen die Rekordstimmung. Rallye bei Palantir, in Deutschland haben Bayer, Lufthansa... ► Artikel lesen |
Das Unternehmen IMMUNOVIA AB kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 0,011 Euro und damit -4,24 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUNOVIA AB finden Sie auf Wallstreet Online.